Nabilone
Overview
Ondansetron (HCl) is oral and parenteral antiemetic agent. Ondansetron (HCl) is the first selective serotonin blocking agent to be marketed. Ondansetron (HCl) is extremely safe and highly effective antiemetic that has greatly improved the ability to give chemotherapy. The quality of life of patients has been tremendously better with ondansetron than with older, traditional antiemetics. Despite its effectiveness, ondansetron is not recommended for the routine treatment of nausea due to its significant cost. Ondansetron was originally approved for the treatment of chemotherapy-induced nausea/vomiting by the FDA in January 1991 and tablets were approved for the treatment of post-operative nausea/vomiting in April 1995. It may have central and/or peripheral action, selectively blocks the serotonin 5-HT1 receptors. 5-HT 1receptors are found centrally in the chemoreceptor trigger zone and peripherally at vagal nerve terminals in the intestines.
Categories
- 17 Gastrointestinal drugs
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Nabilone's dosage details are as follows:
Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
1 to 2 mg | 1.5 (1.5) | 12 hourly | PO | On the day of chemotherapy, the initial dose should be given 1 to 3 hours before the chemotherapeutic agent is administered. To minimize side effects, it is recommended that the lower starting dose be used and that the dose be increased as necessary. A dose of 1 or 2 mg the night before may be useful. |
Paedriatic Dosage (20kg)
|
No data regarding the Paedriatic dosage details of is available. |
Neonatal Dosage (3kg)
|
No data regarding the neonatal dosage details of is available. |
High Risk Groups
Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Back to top
Previous Drug Generic - Next Drug Generic